Dec 30, 2025 • 富途牛牛
SOMEWHAT-BULLISH
Mesoblast Refinances Debt With New $125 Million Credit Facility
Mesoblast Ltd has refinanced its debt with a new $125 million credit facility. This news comes alongside an unrelated financial report from Unity Software, which announced a 35% year-over-year revenue increase to $609 million in its fourth quarter, despite reporting a quarterly loss of 66 cents per share.
Dec 30, 2025 • The Motley Fool Australia
NEUTRAL
Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today
DroneShield, IPD, Mesoblast, and Woodside shares are all experiencing significant gains today due to positive company-specific news and market trends. DroneShield secured a substantial contract, IPD Group made a strategic acquisition, and Mesoblast refinanced its debt, while Woodside Energy benefited from rising oil prices. These developments have led to increased investor confidence and a surge in their respective share prices.
Dec 30, 2025 • Stock Titan
SOMEWHAT-BULLISH
Major shareholder bankrolls Mesoblast with cheaper 5-year loan
Mesoblast has secured a new five-year credit facility for up to US$125 million from director and shareholder Dr. Gregory George, replacing its senior debt at a lower fixed interest rate of 8.00%. The company drew an initial US$75 million to repay existing loans and has the option to draw an additional US$50 million until June 30, 2026. This non-dilutive facility offers more flexibility, no prepayment or exit fees, and does not encumber material assets or intellectual property, though warrants for approximately 323,000 ADSs were issued to Dr. George.
Dec 30, 2025 • Finance News Network
BULLISH
Mesoblast Secures US$75 Million Credit Line, Refinances Debt
Mesoblast Limited refinanced its debt by drawing down US$75 million from a new five-year credit facility provided by director Dr. Gregory George, which features a fixed interest rate of 8.00% per annum, a significant reduction from previous debt facilities. This move fully repaid an existing senior secured loan and partially repaid a subordinated royalty facility, providing Mesoblast with greater financial flexibility. The new facility offers lower overall costs, no early prepayment fees or exit fees, and does not encumber material assets or intellectual property.
Dec 22, 2025 • openPR.com
SOMEWHAT-BULLISH
Stem Cell Therapy Market to Reach US$ 45.69 Billion by 2033
The global Stem Cell Therapy Market, valued at US$ 16.44 billion in 2024, is projected to reach US$ 45.69 billion by 2033, exhibiting a CAGR of 12.7%. This significant growth is attributed to the rising prevalence of chronic diseases, advancements in regenerative medicine, and expanding clinical trials. Key players like Novartis, Bristol Myers Squibb, and Mesoblast are driving innovations in cell and gene therapies for various medical conditions.
Dec 15, 2025 • Biotech Dispatch
NEUTRAL
New analysis finds Mesoblast’s Remestemcel-L outperforms ruxolitinib in severe GvHD
A new meta-analysis presented at ASH found Mesoblast's allogeneic cell therapy, remestemcel-L, showed superior clinical outcomes compared to ruxolitinib for treating steroid-refractory acute graft versus host disease (SR-aGvHD). The analysis, involving 2,732 patients, highlighted remestemcel-L's superior complete and overall remission rates and meaningful differences in adverse events. Ryoncil (remestemcel-L-rknd) is already FDA-approved for children under 12 with SR-aGvHD, and Mesoblast is developing it for adult patients and other inflammatory conditions.